Sign up to save your podcasts
Or
Share Immunotherapy for recurrent or metastatic head and neck squamous cell carcinoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Immunotherapy for recurrent or metastatic head and neck squamous cell carcinoma
touchPANEL DISCUSSION for touchONCOLOGY
Listen to three experts as they explore key clinical considerations when using immune checkpoint inhibitors to treat recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The discussion includes the current role of immune checkpoint inhibitors, factors that may inform treatment decisions and approaches for managing side effects associated with immune checkpoint inhibitors.
The experts
- Prof. Kevin Harrington – The Institute of Cancer Research, London, UK
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Merck and Co., Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/immunotherapy-rmhnscc-practical-considerations/
View all episodes
By touchpodcasttouchPANEL DISCUSSION for touchONCOLOGY
Listen to three experts as they explore key clinical considerations when using immune checkpoint inhibitors to treat recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The discussion includes the current role of immune checkpoint inhibitors, factors that may inform treatment decisions and approaches for managing side effects associated with immune checkpoint inhibitors.
The experts
- Prof. Kevin Harrington – The Institute of Cancer Research, London, UK
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Merck and Co., Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/immunotherapy-rmhnscc-practical-considerations/